Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin
The aim of this study was to characterize the treatment response and tolerability of sofosbuvir plus ribavirin therapies in Japanese patients infected with hepatitis C virus (HCV) genotype (GT)-2. This retrospective study analyzed 114 Japanese HCV GT-2 patients treated for 12 weeks with 400 mg of so...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2017-05-01
|
| Series: | Biology |
| Subjects: | |
| Online Access: | http://www.mdpi.com/2079-7737/6/2/30 |
| _version_ | 1797766186866311168 |
|---|---|
| author | Tatsuo Kanda Masato Nakamura Shin Yasui Yuki Haga Akinobu Tawada Eiichiro Suzuki Yoshihiko Ooka Koji Takahashi Reina Sasaki Shuang Wu Shingo Nakamoto Makoto Arai Fumio Imazeki Osamu Yokosuka |
| author_facet | Tatsuo Kanda Masato Nakamura Shin Yasui Yuki Haga Akinobu Tawada Eiichiro Suzuki Yoshihiko Ooka Koji Takahashi Reina Sasaki Shuang Wu Shingo Nakamoto Makoto Arai Fumio Imazeki Osamu Yokosuka |
| author_sort | Tatsuo Kanda |
| collection | DOAJ |
| description | The aim of this study was to characterize the treatment response and tolerability of sofosbuvir plus ribavirin therapies in Japanese patients infected with hepatitis C virus (HCV) genotype (GT)-2. This retrospective study analyzed 114 Japanese HCV GT-2 patients treated for 12 weeks with 400 mg of sofosbuvir plus weight-based ribavirin daily. This treatment led to higher sustained virologic response at 12-weeks post-treatment (SVR12) rates in both treatment-naïve and treatment-experienced patients. The efficacy of this treatment in compensated cirrhotics was the same as that in patients with chronic hepatitis. HCV GT-2a infection and lower estimated glomerular filtration rates (eGFR) tended to be associated with SVR12. Of 114 patients, 113 completed the combination of sofosbuvir plus ribavirin for 12 weeks. Seven patients without SVR12 did not have HCV NS5B-S282 mutations. The overall SVR12 rate was 90.4% (103 of 114). More effective therapeutic options with less adverse events are desired to achieve higher SVR rates in HCV GT-2 Japanese patients. |
| first_indexed | 2024-03-12T20:21:36Z |
| format | Article |
| id | doaj.art-9ad01998a3454dbdbbc098718bc18528 |
| institution | Directory Open Access Journal |
| issn | 2079-7737 |
| language | English |
| last_indexed | 2024-03-12T20:21:36Z |
| publishDate | 2017-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biology |
| spelling | doaj.art-9ad01998a3454dbdbbc098718bc185282023-08-02T00:55:21ZengMDPI AGBiology2079-77372017-05-01623010.3390/biology6020030biology6020030Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus RibavirinTatsuo Kanda0Masato Nakamura1Shin Yasui2Yuki Haga3Akinobu Tawada4Eiichiro Suzuki5Yoshihiko Ooka6Koji Takahashi7Reina Sasaki8Shuang Wu9Shingo Nakamoto10Makoto Arai11Fumio Imazeki12Osamu Yokosuka13Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, JapanDepartment of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, JapanDepartment of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, JapanDepartment of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, JapanSafety and Health Organization, Chiba University, 1-33 Yayoicho, Inage-ku, Chiba 263-8522, JapanDepartment of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, JapanDepartment of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, JapanDepartment of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, JapanDepartment of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, JapanDepartment of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, JapanDepartment of Molecular Virology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, JapanDepartment of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, JapanSafety and Health Organization, Chiba University, 1-33 Yayoicho, Inage-ku, Chiba 263-8522, JapanDepartment of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, JapanThe aim of this study was to characterize the treatment response and tolerability of sofosbuvir plus ribavirin therapies in Japanese patients infected with hepatitis C virus (HCV) genotype (GT)-2. This retrospective study analyzed 114 Japanese HCV GT-2 patients treated for 12 weeks with 400 mg of sofosbuvir plus weight-based ribavirin daily. This treatment led to higher sustained virologic response at 12-weeks post-treatment (SVR12) rates in both treatment-naïve and treatment-experienced patients. The efficacy of this treatment in compensated cirrhotics was the same as that in patients with chronic hepatitis. HCV GT-2a infection and lower estimated glomerular filtration rates (eGFR) tended to be associated with SVR12. Of 114 patients, 113 completed the combination of sofosbuvir plus ribavirin for 12 weeks. Seven patients without SVR12 did not have HCV NS5B-S282 mutations. The overall SVR12 rate was 90.4% (103 of 114). More effective therapeutic options with less adverse events are desired to achieve higher SVR rates in HCV GT-2 Japanese patients.http://www.mdpi.com/2079-7737/6/2/30genotype 2hepatitis C virusribavirinsofosbuvirtreatment-experienced |
| spellingShingle | Tatsuo Kanda Masato Nakamura Shin Yasui Yuki Haga Akinobu Tawada Eiichiro Suzuki Yoshihiko Ooka Koji Takahashi Reina Sasaki Shuang Wu Shingo Nakamoto Makoto Arai Fumio Imazeki Osamu Yokosuka Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin Biology genotype 2 hepatitis C virus ribavirin sofosbuvir treatment-experienced |
| title | Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin |
| title_full | Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin |
| title_fullStr | Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin |
| title_full_unstemmed | Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin |
| title_short | Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin |
| title_sort | treatment of real world hcv genotype 2 infected japanese patients with sofosbuvir plus ribavirin |
| topic | genotype 2 hepatitis C virus ribavirin sofosbuvir treatment-experienced |
| url | http://www.mdpi.com/2079-7737/6/2/30 |
| work_keys_str_mv | AT tatsuokanda treatmentofrealworldhcvgenotype2infectedjapanesepatientswithsofosbuvirplusribavirin AT masatonakamura treatmentofrealworldhcvgenotype2infectedjapanesepatientswithsofosbuvirplusribavirin AT shinyasui treatmentofrealworldhcvgenotype2infectedjapanesepatientswithsofosbuvirplusribavirin AT yukihaga treatmentofrealworldhcvgenotype2infectedjapanesepatientswithsofosbuvirplusribavirin AT akinobutawada treatmentofrealworldhcvgenotype2infectedjapanesepatientswithsofosbuvirplusribavirin AT eiichirosuzuki treatmentofrealworldhcvgenotype2infectedjapanesepatientswithsofosbuvirplusribavirin AT yoshihikoooka treatmentofrealworldhcvgenotype2infectedjapanesepatientswithsofosbuvirplusribavirin AT kojitakahashi treatmentofrealworldhcvgenotype2infectedjapanesepatientswithsofosbuvirplusribavirin AT reinasasaki treatmentofrealworldhcvgenotype2infectedjapanesepatientswithsofosbuvirplusribavirin AT shuangwu treatmentofrealworldhcvgenotype2infectedjapanesepatientswithsofosbuvirplusribavirin AT shingonakamoto treatmentofrealworldhcvgenotype2infectedjapanesepatientswithsofosbuvirplusribavirin AT makotoarai treatmentofrealworldhcvgenotype2infectedjapanesepatientswithsofosbuvirplusribavirin AT fumioimazeki treatmentofrealworldhcvgenotype2infectedjapanesepatientswithsofosbuvirplusribavirin AT osamuyokosuka treatmentofrealworldhcvgenotype2infectedjapanesepatientswithsofosbuvirplusribavirin |